• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

JPM24: In booming obesity field, Novo Nordisk is 'just getting going,' CEO says

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 10, 2024 at 06:32: PM
via Despite persistent supply hitches since Wegovy’s launch in 2021, Novo Nordisk has quickly garnered blockbuster sales in the newly untapped obesity market. And to hear Novo’s CEO Lars Fruergaard Jørgensen tell it, the company is "just getting going" in the field.

article source
 




Top Bottom
Back
Quote